Clean air for Pharmaxis
Wednesday, 13 August, 2008
Results from the Phase II clinical trial of Pharmaxis' [ASX: PXS] Bronchitol treatment in cystic fibrosis patients have produced promising results.
The study showed that Bronchitol was able to improve lung function in cystic fibrosis sufferers, as measured by forced vital capacity and FEV1 - the amount of air that can be forcibly exhaled in one second.
Improvements in lung function were dose-dependant, with the best results occurring in the patients which had received the highest dose. Pharmaxis has concluded that 400mg is the optimal Bronchitol dose.
Bronchitol is designed to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. It is a proprietary formulation of mannitol, administered as a dry powder through a hand-held inhaler.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
